AR and prostate carcinoma: In turn, androgen receptor and androgen synthesis represent pivotal therapeutic targets (androgen deprivation therapy or ADT), and a variety of anticancer agents targeting this hormonal program has proven to hamper prostate cancer progression [7,8,9].